162 related articles for article (PubMed ID: 23226787)
1. PAI-1 promoter 4G/5G polymorphism (rs1799768) contributes to tumor susceptibility: Evidence from meta-analysis.
Xu X; Xie Y; Lin Y; Xu X; Zhu Y; Mao Y; Hu Z; Wu J; Chen H; Zheng X; Qin J; Xie L
Exp Ther Med; 2012 Dec; 4(6):1127-1133. PubMed ID: 23226787
[TBL] [Abstract][Full Text] [Related]
2. Association Between Plasminogen Activator Inhibitor-1 Genetic Polymorphisms and Stroke Susceptibility.
Hu X; Zan X; Xie Z; Li Y; Lin S; Li H; You C
Mol Neurobiol; 2017 Jan; 54(1):328-341. PubMed ID: 26742513
[TBL] [Abstract][Full Text] [Related]
3. PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.
Wang S; Cao Q; Wang X; Li B; Tang M; Yuan W; Fang J; Qian J; Qin C; Zhang W
PLoS One; 2013; 8(2):e56797. PubMed ID: 23437240
[TBL] [Abstract][Full Text] [Related]
4. Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.
Gao WF; Guo YB; Bai Y; Ding XY; Yan YJ; Wu ZQ
Int Urol Nephrol; 2016 Sep; 48(9):1483-9. PubMed ID: 27272255
[TBL] [Abstract][Full Text] [Related]
5. The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis.
Nie W; Li B; Xiu QY
PLoS One; 2012; 7(3):e34385. PubMed ID: 22479620
[TBL] [Abstract][Full Text] [Related]
6. Plasminogen Activator Inhibitor-1 4G/5G Polymorphism Contributes to Osteonecrosis of the Femoral Head Susceptibility: Evidence from a Systematic Review and Meta-analysis.
Sobhan MR; Mahdinezhad-Yazdi M; Moghimi M; Aghili K; Jafari M; Zare-Shehneh M; Neamatzadeh H
Arch Bone Jt Surg; 2018 Nov; 6(6):468-477. PubMed ID: 30637301
[TBL] [Abstract][Full Text] [Related]
7. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism - a meta-analysis and systematic review.
Zhang Q; Jin Y; Li X; Peng X; Peng N; Song J; Xu M
Vasa; 2020 Mar; 49(2):141-146. PubMed ID: 31920171
[No Abstract] [Full Text] [Related]
8. Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.
Wang J; Wang C; Chen N; Shu C; Guo X; He Y; Zhou Y
Thromb Res; 2014 Dec; 134(6):1241-8. PubMed ID: 25450536
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of the association between plasminogen activator inhibitor-1 4G/5G polymorphism and recurrent pregnancy loss.
Li X; Liu Y; Zhang R; Tan J; Chen L; Liu Y
Med Sci Monit; 2015 Apr; 21():1051-6. PubMed ID: 25862335
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen activator inhibitor-1 4G/5G polymorphism is associated with coronary artery disease risk: a meta-analysis.
Zhang H; Dong P; Yang X; Liu Z
Int J Clin Exp Med; 2014; 7(10):3777-88. PubMed ID: 25419432
[TBL] [Abstract][Full Text] [Related]
11. Association between plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and risk of Alzheimer's disease, metabolic syndrome, and female infertility: A meta-analysis.
Zhang X; Gao B; Xu B
Medicine (Baltimore); 2020 Dec; 99(50):e23660. PubMed ID: 33327353
[TBL] [Abstract][Full Text] [Related]
12. The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) Level and PAI-1 4G/5G Gene Polymorphism with the Formation and the Grade of Endometrial Cancer.
Yıldırım ME; Karakuş S; Kurtulgan HK; Kılıçgün H; Erşan S; Bakır S
Biochem Genet; 2017 Aug; 55(4):314-321. PubMed ID: 28303356
[TBL] [Abstract][Full Text] [Related]
13. Association between plasminogen activator inhibitor-1 -675 4G/5G polymorphism and sepsis: a meta-analysis.
Li L; Nie W; Zhou H; Yuan W; Li W; Huang W
PLoS One; 2013; 8(1):e54883. PubMed ID: 23382992
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen Activator Inhibitor-1 Polymorphism Confers a Genetic Contribution to the Risk of Recurrent Spontaneous Abortion: An Updated Meta-Analysis.
Huang Z; Tang W; Liang Z; Chen Q; Li M; Li Y; Lao S; Pan H; Huang L; Huang M; Hu X; Zhao J
Reprod Sci; 2017 Nov; 24(11):1551-1560. PubMed ID: 28395596
[TBL] [Abstract][Full Text] [Related]
15. PAI-1 Polymorphisms Have Significant Associations With Cancer Risk, Especially Feminine Cancer.
Wang J; Peng Y; Guo H; Li C
Technol Cancer Res Treat; 2021; 20():15330338211037813. PubMed ID: 34521295
[TBL] [Abstract][Full Text] [Related]
16. Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis.
Gong LL; Peng JH; Han FF; Zhu J; Fang LH; Wang YH; Du GH; Wang HY; Liu LH
Thromb Res; 2012 Sep; 130(3):e43-51. PubMed ID: 22771216
[TBL] [Abstract][Full Text] [Related]
17. Plasminogen activator inhibitor-1 -675 4G/5G polymorphism and polycystic ovary syndrome risk: a meta analysis.
Liu Y; Sun MG; Jiang R; Ding R; Che Z; Chen YY; Yao CJ; Zhu XX; Cao JY
J Assist Reprod Genet; 2014 Mar; 31(3):363-70. PubMed ID: 24435452
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.
Lee YH; Song GG
Eur J Obstet Gynecol Reprod Biol; 2014 Apr; 175():8-14. PubMed ID: 24439532
[TBL] [Abstract][Full Text] [Related]
19. Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.
Zhang T; Pang C; Li N; Zhou E; Zhao K
BMC Med; 2013 Jan; 11():1. PubMed ID: 23281898
[TBL] [Abstract][Full Text] [Related]
20. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
